♟️ Thursday 27 August 2026 Thu, 27 Aug 2026

Bentley Capital Limited swung back to profitability in FY2026, posting a $255,000 net profit driven mainly by legal settlements and modest investment gains, reversing a prior loss of $878,000.

Wiseway Group delivered 10.1% revenue growth to $205.6 million in FY26, led by a 22.2% surge in its eCommerce Solutions division, while maintaining EBITDA margins amid cost discipline. The Group declared a fully franked final dividend of 0.6 cents per share.

Revolution Private Credit Income Trust (ASX: REV) posted a 6.25% net return for its inaugural period, outperforming its benchmark, and executed an on-market buy-back worth $23 million.

NEXTDC has swung to a statutory profit of $82.1 million in FY26, driven by a record 202% jump in contracted utilisation and a strategic shift in lease accounting that added a $128.8 million fair value gain. The company’s $3.4 billion capital expenditure underscores its aggressive expansion, including the opening of its first international data centre in Kuala Lumpur.

Dubber Corporation Limited (ASX:DUB) posted a 17% revenue drop in FY26 to $35.1 million, mainly due to a major contract loss in Europe, but narrowed its net loss by 78% excluding impairments and achieved cash flow breakeven in H2.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Alfabs Australia delivered an 11% revenue increase and improved free cash flow in FY26, progressing its debt restructuring and setting the stage for dividend reinstatement.

Beonic Limited grew revenue by 5.2% to $23.3 million in FY26, halving its loss and achieving positive operating cash flow, underpinned by a landmark Moroccan airport contract and product innovation.

Australian Dairy Nutritionals reported a 47% reduction in net loss for FY26, driven by a 66% revenue jump in its nutritional powders segment, which now makes up 70% of total revenue.

Industrial Minerals Ltd has finalised its takeover of Galleon Metals, adding a 205km² gold exploration portfolio in WA’s Eastern Goldfields. The company also announced key board appointments, including a new Managing Director with direct Laverton expertise.

Regal Investment Fund posted a standout FY2026 with a 17.32% net return, tripling operating profit to $117.9 million and continuing its on-market buy-back program.

Anson Resources' downstream partner JordProxa has produced lithium carbonate at 99.6% purity from its Green River project, exceeding the 99.5% industry benchmark for electric vehicle batteries. Independent SGS testing confirmed the quality, highlighting progress toward commercial lithium supply.

Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.

RocketBoots reported a 9.7% revenue rise to A$724,815 but deepened its net loss to A$6.6 million, driven by heavy investment ahead of a major contract rollout and international growth.

MA Credit Income Trust (ASX:MA1) posted a robust 8.56% net return for FY2026, surpassing its target, alongside a fully subscribed $190.5 million capital raise and strategic buy-back initiatives.

Pengana Private Equity Trust (ASX: PE1) posted a 23.2% net return for FY2026, powered by a dramatic revaluation of SpaceX and strong gains across a diversified private equity portfolio.

Winton Land’s governance is under strain after independent directors Steven Joyce and Guy Fergusson resigned citing conflicts with the majority shareholder. The board must urgently appoint new independent directors to maintain NZX compliance and avoid potential trading suspension.

Saferoads Holdings (ASX:SRH) doubled its revenue to $12.47 million in FY2026, swinging to a $711,000 profit from continuing operations after divesting its Road Safety Rental business. The company declared a fully franked final dividend of 0.5 cents per share.

Biotron Limited posted a $1.52 million net loss for FY2026, driven by integration and R&D costs following its Sedarex acquisition, while progressing regulatory and clinical development for its SedRxTM anaesthetic and antiviral pipeline.

SenSen Networks reported a 16.7% rise in annualised recurring revenue to $11.7 million and a 23.6% EBITDA increase to $2.0 million in FY26, while expanding its SenDISA platform into environmental enforcement with EPA Victoria.

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.

Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.

Aeris Resources delivered a standout FY26 with revenues up 22% and profit after tax surging 295%, buoyed by operational gains and a strategic acquisition of Peel Mining.

Careteq Limited (ASX: CTQ) reported a $398K net loss for FY26 amid a strategic reset that included selling its Embedded Health Solutions business and repaying all debt. The company now pivots fully to growing its HMR Referrals platform with $3.19 million cash on hand.